Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Intermediate Risk Non-Muscle Invasive Bladder Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Not applicableStudy completedNCT04319263
What this trial is testing

Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Mansoura University 1,600
Testing effectiveness (Phase 2)Study completedNCT03914794
What this trial is testing

Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Who this might be right for
Bladder CancerNMIBCNon-Muscle Invasive Bladder Cancer+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 30
Testing effectiveness (Phase 2)Study completedNCT00491114
What this trial is testing

Intravesical Chemotherapy Treatment of Superficial Bladder Cancer

Who this might be right for
Bladder Neoplasms
Eli Lilly and Company 8
Large-scale testing (Phase 3)WithdrawnNCT07313891
What this trial is testing

Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) CancerUrothelial Carcinoma Bladder+1 more
Relmada Therapeutics, Inc.
Testing effectiveness (Phase 2)Study completedNCT00595088
What this trial is testing

Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

Who this might be right for
Superficial Bladder Cancer
Anchiano Therapeutics Israel Ltd. 47
Testing effectiveness (Phase 2)Ended earlyNCT03167151
What this trial is testing

Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Non-muscle Invasive Bladder Cancer (NMIBC)
University of Oxford 6
Large-scale testing (Phase 3)UnknownNCT00816075
What this trial is testing

Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection

Who this might be right for
Recurrent Superficial Bladder CancerDistilled Water
Bozyaka Training and Research Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT06637423
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Who this might be right for
Non-Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 32
Large-scale testing (Phase 3)Ended earlyNCT04688931
What this trial is testing

UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 282
Not applicableStudy completedNCT06768346
What this trial is testing

Hyperthermic Intra-Vesical Chemotherapy

Who this might be right for
Bladder Cancer
Queen Mary University of London 259
Testing effectiveness (Phase 2)Looking for participantsNCT07646145
What this trial is testing

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shanxi Province Cancer Hospital 30
Not applicableStudy completedNCT02298998
What this trial is testing

Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study

Who this might be right for
Bladder Cancer
The University of Texas Health Science Center at San Antonio 41
Not applicableLooking for participantsNCT05825950
What this trial is testing

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Non-muscle-invasive Bladder Cancer
University of Texas Southwestern Medical Center 600
Testing effectiveness (Phase 2)Looking for participantsNCT06995677
What this trial is testing

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc 90
Not applicableStudy completedNCT03664258
What this trial is testing

A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)

Who this might be right for
Non-muscle-invasive Bladder Cancer
Cepheid 852
Testing effectiveness (Phase 2)UnknownNCT05975151
What this trial is testing

Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Qilu Hospital of Shandong University 63